Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Shares, par value CHF 0.08 per share
-
Shares outstanding
-
112M
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
34M
-
Shares change
-
-6.95M
-
Total reported value, excl. options
-
$56.4M
-
Value change
-
-$6.84M
-
Number of buys
-
11
-
Number of sells
-
-20
-
Price
-
$1.66
Significant Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q4 2023
49 filings reported holding ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share as of Q4 2023.
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34M shares
of 112M outstanding shares and own 30.34% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (15.3M shares), Prosight Management, LP (6.47M shares), MILLENNIUM MANAGEMENT LLC (2.67M shares), CITADEL ADVISORS LLC (1.85M shares), BANK OF AMERICA CORP /DE/ (1.53M shares), GOLDMAN SACHS GROUP INC (1.46M shares), Affinity Asset Advisors, LLC (1.01M shares), Vantage Consulting Group Inc (851K shares), MORGAN STANLEY (782K shares), and Blue Owl Capital Holdings LP (734K shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.